Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$2.85 +2.9%	$2.13	$1.10 ▼ $3.24	$158.41M	3.03	246,644 shs	17,913 shs
CRBU Caribou Biosciences	$1.85 +0.5%	$1.73	$0.66 ▼ $3.00	$172.28M	2.55	1.27 million shs	1.40 million shs
DTIL Precision BioSciences	$4.96 +4.6%	$4.65	$3.61 ▼ $11.09	$58.46M	1.52	84,524 shs	65,715 shs
SGMO Sangamo Therapeutics	$0.59 +2.3%	$0.52	$0.41 ▼ $3.18	$176.89M	1.18	6.63 million shs	5.09 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	0.00%	0.00%	+42.50%	+93.88%	+21.02%
CRBU Caribou Biosciences	0.00%	-6.57%	-21.94%	+81.37%	-17.04%
DTIL Precision BioSciences	0.00%	+5.31%	-0.80%	+8.30%	-49.54%
SGMO Sangamo Therapeutics	0.00%	+1.09%	-1.91%	+23.87%	-32.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLLS Cellectis	3.4002 of 5 stars	3.5	5.0	0.0	3.3	2.5	0.0
CRBU Caribou Biosciences	2.7317 of 5 stars	3.5	5.0	0.0	1.5	1.7	0.0
DTIL Precision BioSciences	4.0706 of 5 stars	3.5	1.0	4.6	2.9	1.7	0.6
SGMO Sangamo Therapeutics	2.7614 of 5 stars	3.3	4.0	0.0	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	3.00	Buy	$4.00	40.35% Upside
CRBU Caribou Biosciences	3.00	Buy	$6.67	260.36% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	847.58% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$4.50	667.53% Upside

Current Analyst Ratings Breakdown

Latest CRBU, CLLS, DTIL, and SGMO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/24/2025	SGMO Sangamo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$49.22M	3.22	N/A	N/A	$1.75 per share	1.63
CRBU Caribou Biosciences	$9.99M	17.24	N/A	N/A	$1.78 per share	1.04
DTIL Precision BioSciences	$68.70M	0.85	N/A	N/A	$2.89 per share	1.72
SGMO Sangamo Therapeutics	$57.80M	3.06	N/A	N/A	$0.06 per share	9.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$36.76M	-$0.82	N/A	N/A	N/A	-100.69%	-68.05%	-21.53%	11/3/2025 (Estimated)
CRBU Caribou Biosciences	-$149.10M	-$1.78	N/A	N/A	N/A	-1,800.93%	-62.35%	-49.65%	11/5/2025 (Estimated)
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
SGMO Sangamo Therapeutics	-$97.94M	-$0.29	N/A	N/A	N/A	-77.48%	-293.05%	-63.85%	11/11/2025 (Estimated)

Latest CRBU, CLLS, DTIL, and SGMO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	-$0.35	+$0.05	-$0.58	$1.64 million	$2.67 million
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million
8/7/2025	Q2 2025	SGMO Sangamo Therapeutics	-$0.07	-$0.08	-$0.01	-$0.08	$31.68 million	$18.31 million
8/4/2025	Q2 2025	CLLS Cellectis	-$0.15	-$0.24	-$0.09	-$0.24	$10.07 million	$18.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	0.58	1.38	1.38
CRBU Caribou Biosciences	N/A	6.66	6.66
DTIL Precision BioSciences	0.66	5.18	5.18
SGMO Sangamo Therapeutics	N/A	1.05	1.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
CRBU Caribou Biosciences	77.51%
DTIL Precision BioSciences	37.99%
SGMO Sangamo Therapeutics	56.93%

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
CRBU Caribou Biosciences	8.28%
DTIL Precision BioSciences	4.50%
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
CRBU Caribou Biosciences	100	93.12 million	85.41 million	Optionable
DTIL Precision BioSciences	200	11.79 million	11.26 million	No Data
SGMO Sangamo Therapeutics	480	301.71 million	289.34 million	Optionable

CRBU, CLLS, DTIL, and SGMO Headlines

Recent News About These Companies

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Down 41.5% in July

August 20, 2025 | marketbeat.com

Sangamo Therapeutics (NASDAQ:SGMO) Raised to "Hold" at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Q3 EPS Forecast for Sangamo Therapeutics Boosted by Analyst

August 17, 2025 | marketbeat.com

Wall Street Zen Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to "Hold"

August 17, 2025 | marketbeat.com

Analysts Issue Forecasts for SGMO Q4 Earnings

August 16, 2025 | marketbeat.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.50 Consensus PT from Brokerages

August 16, 2025 | americanbankingnews.com

HC Wainwright Analysts Raise Earnings Estimates for SGMO

August 16, 2025 | americanbankingnews.com

What Makes Sangamo (SGMO) a New Buy Stock

August 14, 2025 | zacks.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of "Moderate Buy" from Brokerages

August 14, 2025 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Zimmer Biomet Holdings (ZBH)

August 9, 2025 | theglobeandmail.com

Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

GSA Capital Partners LLP Boosts Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

August 4, 2025 | marketbeat.com

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

July 31, 2025 | globenewswire.com

Sangamo Therapeutics (SGMO) Expected to Announce Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy

July 25, 2025 | msn.com

H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data

July 3, 2025 | msn.com

SGMO - Sangamo Therapeutics Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Morningstar

June 25, 2025 | morningstar.comM

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire

June 25, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU, CLLS, DTIL, and SGMO Company Descriptions

Cellectis NASDAQ:CLLS

$2.82 +0.05 (+1.81%)

As of 08/22/2025 04:00 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Caribou Biosciences NASDAQ:CRBU

$1.85 +0.01 (+0.54%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.83 -0.02 (-1.08%)

As of 08/22/2025 07:39 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Precision BioSciences NASDAQ:DTIL

$4.96 +0.22 (+4.64%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.94 -0.01 (-0.30%)

As of 08/22/2025 06:31 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Sangamo Therapeutics NASDAQ:SGMO

$0.59 +0.01 (+2.29%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.58 -0.01 (-1.59%)

As of 08/22/2025 07:59 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time